Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.1% – Should You Sell?

Eli Lilly and Company (NYSE:LLY) was down 2.1% on Friday . The stock traded as low as $1,063.02 and last traded at $1,065.05. Approximately 2,572,729 shares were traded during trading, a decline of 15% from the average daily volume of 3,022,170 shares. The stock had previously closed at $1,087.38.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bernstein raised conviction on LLY, projecting a $1,300 target on expectations that Lilly’s weight‑loss pill will be a blockbuster — this supports upside and keeps buy-side interest alive. Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share
• Positive Sentiment: Pipeline progress: Lilly reported advancement of early‑stage LY4064809, signaling continued R&D momentum that can de‑risk future growth beyond GLP‑1s. Eli Lilly Advances Early-Stage LY4064809 Study
• Positive Sentiment: Device/delivery gains: Lilly completed a device study for remternetug delivery options — positive for convenience/uptake and formulary discussions. Eli Lilly Advances Remternetug Delivery Options With Completed Device Study
• Positive Sentiment: Late‑stage obesity program: Lilly launched a Phase 3b dosing study for retatrutide, which, if successful, strengthens near‑term growth visibility in obesity. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Oncology tailwind: Analyst pieces highlight Verzenio and new oncology launches as incremental revenue drivers that broaden the story beyond GLP‑1s. Here’s How Eli Lilly’s Oncology Drugs Are Poised Ahead of Q4 Earnings
• Neutral Sentiment: Industry outlook: Executives at JPMorgan H.C. said the obesity market will expand into more pills, combos and easier access — a market‑wide constructive view but it raises competitive and margin questions. What obesity drugmakers see next in the market
• Neutral Sentiment: Corporate moves: Lilly named Pranav Shroff director of marketing — a routine leadership update with limited near‑term financial impact. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Critical take: Opinion pieces urge investors to consider alternatives to Lilly, arguing the stock’s high valuation is driven largely by GLP‑1 enthusiasm — this kind of narrative can trigger profit‑taking. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
• Negative Sentiment: Competition risk: Sun Pharma won a Wegovy generic nod in India, setting up tougher pricing/market dynamics in a key growth market for obesity drugs. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market
• Negative Sentiment: Regulatory/legal headline: Coverage of a lawsuit over insulin pricing keeps regulatory and reputational risk in focus for investors. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

Analyst Ratings Changes

Several equities analysts have commented on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Wednesday, January 14th. Wolfe Research increased their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research report on Monday, December 1st. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Four research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Trading Down 2.1%

The business’s 50 day simple moving average is $1,056.39 and its 200 day simple moving average is $878.04. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.11, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 33.86%.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently modified their holdings of the stock. R. W. Roge & Company Inc. boosted its holdings in shares of Eli Lilly and Company by 18.7% in the fourth quarter. R. W. Roge & Company Inc. now owns 653 shares of the company’s stock valued at $701,000 after acquiring an additional 103 shares in the last quarter. Freestone Capital Holdings LLC lifted its position in Eli Lilly and Company by 5.1% in the fourth quarter. Freestone Capital Holdings LLC now owns 28,539 shares of the company’s stock valued at $30,671,000 after purchasing an additional 1,384 shares during the period. Octavia Wealth Advisors LLC lifted its position in Eli Lilly and Company by 23.9% in the fourth quarter. Octavia Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $807,000 after purchasing an additional 145 shares during the period. Cura Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 51.8% in the 4th quarter. Cura Wealth Advisors LLC now owns 867 shares of the company’s stock valued at $932,000 after purchasing an additional 296 shares in the last quarter. Finally, Natural Investments LLC increased its position in Eli Lilly and Company by 0.7% during the 4th quarter. Natural Investments LLC now owns 5,414 shares of the company’s stock worth $5,817,000 after purchasing an additional 39 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.